Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrea Armirotti is active.

Publication


Featured researches published by Andrea Armirotti.


Nature Communications | 2017

Astrocyte deletion of Bmal1 alters daily locomotor activity and cognitive functions via GABA signalling

Olga Barca-Mayo; Meritxell Pons-Espinal; Philipp Follert; Andrea Armirotti; Luca Berdondini; Davide De Pietri Tonelli

Circadian rhythms are controlled by a network of clock neurons in the central pacemaker, the suprachiasmatic nucleus (SCN). Core clock genes, such as Bmal1, are expressed in SCN neurons and in other brain cells, such as astrocytes. However, the role of astrocytic clock genes in controlling rhythmic behaviour is unknown. Here we show that ablation of Bmal1 in GLAST-positive astrocytes alters circadian locomotor behaviour and cognition in mice. Specifically, deletion of astrocytic Bmal1 has an impact on the neuronal clock through GABA signalling. Importantly, pharmacological modulation of GABAA-receptor signalling completely rescues the behavioural phenotypes. Our results reveal a crucial role of astrocytic Bmal1 for the coordination of neuronal clocks and propose a new cellular target, astrocytes, for neuropharmacology of transient or chronic perturbation of circadian rhythms, where alteration of astrocytic clock genes might contribute to the impairment of the neurobehavioural outputs such as cognition.


Acta Neuropathologica | 2016

Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet.

Anna Rocchi; Carmelo Milioto; Sara Parodi; Andrea Armirotti; Doriana Borgia; Matteo Pellegrini; Anna Urciuolo; Sibilla Molon; Valeria Morbidoni; Manuela Marabita; Vanina Romanello; Pamela Gatto; Bert Blaauw; Paolo Bonaldo; Diane M. Robins; Andrew P. Lieberman; Gianni Sorarù; Lodovica Vergani; Marco Sandri; Maria Pennuto

Spinal and bulbar muscular atrophy (SBMA) is a neuromuscular disease caused by the expansion of a polyglutamine tract in the androgen receptor (AR). The mechanism by which expansion of polyglutamine in AR causes muscle atrophy is unknown. Here, we investigated pathological pathways underlying muscle atrophy in SBMA knock-in mice and patients. We show that glycolytic muscles were more severely affected than oxidative muscles in SBMA knock-in mice. Muscle atrophy was associated with early-onset, progressive glycolytic-to-oxidative fiber-type switch. Whole genome microarray and untargeted lipidomic analyses revealed enhanced lipid metabolism and impaired glycolysis selectively in muscle. These metabolic changes occurred before denervation and were associated with a concurrent enhancement of mechanistic target of rapamycin (mTOR) signaling, which induced peroxisome proliferator-activated receptor γ coactivator 1 alpha (PGC1α) expression. At later stages of disease, we detected mitochondrial membrane depolarization, enhanced transcription factor EB (TFEB) expression and autophagy, and mTOR-induced protein synthesis. Several of these abnormalities were detected in the muscle of SBMA patients. Feeding knock-in mice a high-fat diet (HFD) restored mTOR activation, decreased the expression of PGC1α, TFEB, and genes involved in oxidative metabolism, reduced mitochondrial abnormalities, ameliorated muscle pathology, and extended survival. These findings show early-onset and intrinsic metabolic alterations in SBMA muscle and link lipid/glucose metabolism to pathogenesis. Moreover, our results highlight an HFD regime as a promising approach to support SBMA patients.


Stem Cells Translational Medicine | 2017

First Characterization of Human Amniotic Fluid Stem Cell Extracellular Vesicles as a Powerful Paracrine Tool Endowed with Regenerative Potential

Carolina Balbi; Martina Piccoli; Lucio Barile; Andrea Papait; Andrea Armirotti; Elisa Principi; Daniele Reverberi; Luisa Pascucci; Pamela Becherini; Luigi Varesio; Massimo Mogni; Domenico A. Coviello; Tiziano Bandiera; Michela Pozzobon; Ranieri Cancedda; Sveva Bollini

Human amniotic fluid stem cells (hAFS) have shown a distinct secretory profile and significant regenerative potential in several preclinical models of disease. Nevertheless, little is known about the detailed characterization of their secretome. Herein we show for the first time that hAFS actively release extracellular vesicles (EV) endowed with significant paracrine potential and regenerative effect. c‐KIT+ hAFS were isolated from leftover samples of amniotic fluid from prenatal screening and stimulated to enhance EV release (24 hours 20% O2 versus 1% O2 preconditioning). The capacity of the c‐KIT+ hAFS‐derived EV (hAFS‐EV) to induce proliferation, survival, immunomodulation, and angiogenesis were investigated in vitro and in vivo. The hAFS‐EV regenerative potential was also assessed in a model of skeletal muscle atrophy (HSA‐Cre, SmnF7/F7 mice), in which mouse AFS transplantation was previously shown to enhance muscle strength and survival. hAFS secreted EV ranged from 50 up to 1,000 nm in size. In vitro analysis defined their role as biological mediators of regenerative, paracrine effects while their modulatory role in decreasing skeletal muscle inflammation in vivo was shown for the first time. Hypoxic preconditioning significantly induced the enrichment of exosomes endowed with regenerative microRNAs within the hAFS‐EV. In conclusion, this is the first study showing that c‐KIT+ hAFS dynamically release EV endowed with remarkable paracrine potential, thus representing an appealing tool for future regenerative therapy. Stem Cells Translational Medicine 2017;6:1340–1355


Journal of Medicinal Chemistry | 2016

Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain

Margherita Brindisi; Samuele Maramai; Sandra Gemma; Simone Brogi; Alessandro Grillo; Lorenzo Di Cesare Mannelli; Emanuele Gabellieri; Stefania Lamponi; Simona Saponara; Beatrice Gorelli; Daniele Tedesco; Tommaso Bonfiglio; Christophe Landry; Kwang-Mook Jung; Andrea Armirotti; Livio Luongo; Alessia Ligresti; Fabiana Piscitelli; Carlo Bertucci; Marie Pierre Dehouck; Giuseppe Campiani; Sabatino Maione; Carla Ghelardini; Anna Pittaluga; Daniele Piomelli; Vincenzo Di Marzo; Stefania Butini

We report the discovery of compound 4a, a potent β-lactam-based monoacylglycerol lipase (MGL) inhibitor characterized by an irreversible and stereoselective mechanism of action, high membrane permeability, high brain penetration evaluated using a human in vitro blood-brain barrier model, high selectivity in binding and affinity-based proteomic profiling assays, and low in vitro toxicity. Mode-of-action studies demonstrate that 4a, by blocking MGL, increases 2-arachidonoylglycerol and behaves as a cannabinoid (CB1/CB2) receptor indirect agonist. Administration of 4a in mice suffering from experimental autoimmune encephalitis ameliorates the severity of the clinical symptoms in a CB1/CB2-dependent manner. Moreover, 4a produced analgesic effects in a rodent model of acute inflammatory pain, which was antagonized by CB1 and CB2 receptor antagonists/inverse agonists. 4a also relieves the neuropathic hypersensitivity induced by oxaliplatin. Given these evidence, 4a, as MGL selective inhibitor, could represent a valuable lead for the future development of therapeutic options for multiple sclerosis and chronic pain.


ACS Chemical Biology | 2015

Activity-Based Probe for N-Acylethanolamine Acid Amidase

Elisa Romeo; Stefano Ponzano; Andrea Armirotti; Maria Summa; Fabio Bertozzi; Gianpiero Garau; Tiziano Bandiera; Daniele Piomelli

N-Acylethanolamine acid amidase (NAAA) is a lysosomal cysteine hydrolase involved in the degradation of saturated and monounsaturated fatty acid ethanolamides (FAEs), a family of endogenous lipid signaling molecules that includes oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). Among the reported NAAA inhibitors, α-amino-β-lactone (3-aminooxetan-2-one) derivatives have been shown to prevent FAE hydrolysis in innate-immune and neural cells and to reduce reactions to inflammatory stimuli. Recently, we disclosed two potent and selective NAAA inhibitors, the compounds ARN077 (5-phenylpentyl-N-[(2S,3R)-2-methyl-4-oxo-oxetan-3-yl]carbamate) and ARN726 (4-cyclohexylbutyl-N-[(S)-2-oxoazetidin-3-yl]carbamate). The former is active in vivo by topical administration in rodent models of hyperalgesia and allodynia, while the latter exerts systemic anti-inflammatory effects in mouse models of lung inflammation. In the present study, we designed and validated a derivative of ARN726 as the first activity-based protein profiling (ABPP) probe for the in vivo detection of NAAA. The newly synthesized molecule 1 is an effective in vitro and in vivo click-chemistry activity based probe (ABP), which is able to capture the catalytically active form of NAAA in Human Embryonic Kidney 293 (HEK293) cells overexpressing human NAAA as well as in rat lung tissue. Competitive ABPP with 1 confirmed that ARN726 and ARN077 inhibit NAAA in vitro and in vivo. Compound 1 is a useful new tool to identify activated NAAA both in vitro and in vivo and to investigate the physiological and pathological roles of this enzyme.


Metabolomics | 2016

Ion mobility mass spectrometry enhances low-abundance species detection in untargeted lipidomics.

Abdul W. Basit; Silvia Pontis; Daniele Piomelli; Andrea Armirotti

We describe a simple method for the detection of low intensity lipid signals in complex tissue samples, based on a combination of liquid chromatography/mass spectrometry and ion mobility mass spectrometry. The method relies on visual and software-assisted analysis of overlapped mobilograms (diagrams of mass-to-charge ratio, m/z, vs drift time, DT) and was successfully applied in untargeted lipidomics analyses of mouse brain tissue to detect relatively small variations in a scarce class of phospholipids (N-acyl phosphatidylethanolamines) generated during neural tissue damage, against a background of hundreds of lipid species. Standard analytical tools, including Principal Component Analysis, failed to detect such changes.


European Journal of Medicinal Chemistry | 2016

Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies

Marco Migliore; Damien Habrant; Oscar Sasso; Clara Albani; Sine Mandrup Bertozzi; Andrea Armirotti; Daniele Piomelli; Rita Scarpelli

Non-steroidal anti-inflammatory drugs (NSAIDs) exert their pharmacological effects by inhibiting cyclooxygenase (COX)-1 and COX-2. Though widely prescribed for pain and inflammation, these agents have limited utility in chronic diseases due to serious mechanism-based adverse events such as gastrointestinal damage. Concomitant blockade of fatty acid amide hydrolase (FAAH) enhances the therapeutic effects of the NSAIDs while attenuating their propensity to cause gastrointestinal injury. This favorable interaction is attributed to the accumulation of protective FAAH substrates, such as the endocannabinoid anandamide, and suggests that agents simultaneously targeting COX and FAAH might provide an innovative strategy to combat pain and inflammation with reduced side effects. Here, we describe the rational design and structure-active relationship (SAR) properties of the first class of potent multitarget FAAH-COX inhibitors. A focused SAR exploration around the prototype 10r (ARN2508) led to the identification of achiral (18b) as well as racemic (29a-c and 29e) analogs. Absolute configurational assignment and pharmacological evaluation of single enantiomers of 10r are also presented. (S)-(+)-10r is the first highly potent and selective chiral inhibitor of FAAH-COX with marked inxa0vivo activity, and represents a promising lead to discover novel analgesics and anti-inflammatory drugs.


Scientific Reports | 2017

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.

Alba Di Pardo; Enrico Amico; Abdul W. Basit; Andrea Armirotti; Piyush Joshi; Diana M. Neely; Romina Vuono; Salvatore Castaldo; Anna F. Digilio; Francesco Scalabrì; Giuseppe Pepe; Francesca Elifani; Michele Madonna; Se Kyoo Jeong; Bu-Mahn Park; Maurizio D’Esposito; Aaron B. Bowman; Roger A. Barker; Vittorio Maglione

Huntington’s disease is characterized by a complex and heterogeneous pathogenic profile. Studies have shown that disturbance in lipid homeostasis may represent a critical determinant in the progression of several neurodegenerative disorders. The recognition of perturbed lipid metabolism is only recently becoming evident in HD. In order to provide more insight into the nature of such a perturbation and into the effect its modulation may have in HD pathology, we investigated the metabolism of Sphingosine-1-phosphate (S1P), one of the most important bioactive lipids, in both animal models and patient samples. Here, we demonstrated that S1P metabolism is significantly disrupted in HD even at early stage of the disease and importantly, we revealed that such a dysfunction represents a common denominator among multiple disease models ranging from cells to humans through mouse models. Interestingly, the in vitro anti-apoptotic and the pro-survival actions seen after modulation of S1P-metabolizing enzymes allows this axis to emerge as a new druggable target and unfolds its promising therapeutic potential for the development of more effective and targeted interventions against this incurable condition.


Proceedings of the National Academy of Sciences of the United States of America | 2016

Endogenous N-acyl taurines regulate skin wound healing

Oscar Sasso; Silvia Pontis; Andrea Armirotti; Giorgia Cardinali; Daniela Kovacs; Marco Migliore; Maria Summa; Guillermo Moreno-Sanz; Mauro Picardo; Daniele Piomelli

Significance Healthy human skin quickly repairs itself when wounded. Skin healing is essential for survival, and it depends on a well-ordered sequence of molecular and cellular events that require the cooperation of several growth-promoting proteins released by skin cells or produced in the extracellular matrix. In the present study, we identify a family of lipid-derived molecules that accelerate the closure of self-repairing skin wounds. These endogenous substances promote migration of epidermal keratinocytes and differentiation of dermal fibroblasts by recruiting intracellular signals similar to those engaged by protein growth factors. Understanding this unprecedented mechanism of wound-healing control may guide new therapeutic approaches to the management of chronic wounds in patients with diabetes, bed-ridden elderly people with pressure ulcers, and immunosuppressed recipients of organ transplants. The intracellular serine amidase, fatty acid amide hydrolase (FAAH), degrades a heterogeneous family of lipid-derived bioactive molecules that include amides of long-chain fatty acids with taurine [N-acyl-taurines (NATs)]. The physiological functions of the NATs are unknown. Here we show that genetic or pharmacological disruption of FAAH activity accelerates skin wound healing in mice and stimulates motogenesis of human keratinocytes and differentiation of human fibroblasts in primary cultures. Using untargeted and targeted lipidomics strategies, we identify two long-chain saturated NATs—N-tetracosanoyl-taurine [NAT(24:0)] and N-eicosanoyl-taurine [NAT(20:0)]—as primary substrates for FAAH in mouse skin, and show that the levels of these substances sharply decrease at the margins of a freshly inflicted wound to increase again as healing begins. Additionally, we demonstrate that local administration of synthetic NATs accelerates wound closure in mice and stimulates repair-associated responses in primary cultures of human keratinocytes and fibroblasts, through a mechanism that involves tyrosine phosphorylation of the epidermal growth factor receptor and an increase in intracellular calcium levels, under the permissive control of transient receptor potential vanilloid-1 receptors. The results point to FAAH-regulated NAT signaling as an unprecedented lipid-based mechanism of wound-healing control in mammalian skin, which might be targeted for chronic wound therapy.


British Journal of Pharmacology | 2017

5‐fluorouracil causes endothelial cell senescence: potential protective role of glucagon‐like peptide 1

Paola Altieri; Roberto Murialdo; Chiara Barisione; Edoardo Lazzarini; Silvano Garibaldi; Patrizia Fabbi; Clarissa Ruggeri; Silvia Borile; Federico Carbone; Andrea Armirotti; Marco Canepa; Alberto Ballestrero; Claudio Brunelli; Fabrizio Montecucco; Pietro Ameri; Paolo Spallarossa

5‐fluorouracil (5FU) and its prodrug, capecitabine, can damage endothelial cells, whilst endothelial integrity is preserved by glucagon‐like peptide 1 (GLP‐1). Here, we studied the effect of 5FU on endothelial senescence and whether GLP‐1 antagonizes it.

Collaboration


Dive into the Andrea Armirotti's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Abdul W. Basit

University College London

View shared research outputs
Top Co-Authors

Avatar

Tiziano Bandiera

Istituto Italiano di Tecnologia

View shared research outputs
Top Co-Authors

Avatar

Maria Summa

Istituto Italiano di Tecnologia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Clarissa Braccia

Istituto Italiano di Tecnologia

View shared research outputs
Top Co-Authors

Avatar

Davide De Pietri Tonelli

Istituto Italiano di Tecnologia

View shared research outputs
Top Co-Authors

Avatar

Giuliana Ottonello

Istituto Italiano di Tecnologia

View shared research outputs
Top Co-Authors

Avatar

Jose M. Arencibia

Istituto Italiano di Tecnologia

View shared research outputs
Top Co-Authors

Avatar

Luca Bono

Istituto Italiano di Tecnologia

View shared research outputs
Researchain Logo
Decentralizing Knowledge